Sionna Therapeutics (NASDAQ:SION) Earns Outperform Rating from Analysts at Wedbush

Key Points

• Wedbush initiated coverage with an “Outperform” rating and a $53 price target (about a 31% upside), joining other bullish analysts and contributing to a MarketBeat consensus of a “Moderate Buy” and a $53 consensus target.
• Shares opened around $40.45 with a market cap of $1.83 billion; Sionna beat last quarter’s EPS (‑$0.46 vs. est. ‑$0.61) but analysts still forecast about ‑$2.44 EPS for the current fiscal year.
• Significant insider selling occurred: directors executed sales under Rule 10b5‑1 and insiders sold 1,131,856 shares (~$50.8M) over the last quarter, with company insiders now owning about 3.9% of the stock.

Research analysts at Wedbush initiated coverage on shares of Sionna Therapeutics (NASDAQ:SION - Get Free Report) in a note issued to investors on Tuesday, Marketbeat.com reports. The firm set an "outperform" rating and a $53.00 price target on the stock. Wedbush's target price points to a potential upside of 31.03% from the company's previous close.

Other equities analysts have also issued reports about the stock. Guggenheim raised their price objective on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Monday, March 2nd. Raymond James Financial restated a "strong-buy" rating and issued a $53.00 price objective on shares of Sionna Therapeutics in a research report on Monday, January 5th. JonesTrading raised their price objective on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the company a "buy" rating in a research report on Tuesday, April 28th. BTIG Research restated a "buy" rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a research report on Monday, April 27th. Finally, Citigroup initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday, February 24th. They issued an "outperform" rating for the company. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $53.00.

Get Sionna Therapeutics SMS alerts:

Sign Up

Sionna Therapeutics Stock Up 3.3%

Shares of NASDAQ:SION opened at $40.45 on Tuesday. The firm has a market capitalization of $1.83 billion, a PE ratio of -20.74 and a beta of 1.35. Sionna Therapeutics has a twelve month low of $11.77 and a twelve month high of $46.46. The company has a 50-day moving average price of $38.18 and a two-hundred day moving average price of $39.13.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.15. Analysts anticipate that Sionna Therapeutics will post -2.44 earnings per share for the current fiscal year.

Insider Activity at Sionna Therapeutics

In other Sionna Therapeutics news, Director Peter A. Thompson sold 2,948 shares of Sionna Therapeutics stock in a transaction that occurred on Saturday, April 18th. The shares were sold at an average price of $44.52, for a total transaction of $131,244.96. Following the completion of the sale, the director directly owned 2,964,774 shares in the company, valued at $131,991,738.48. The trade was a 0.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 2,948 shares of Sionna Therapeutics stock in a transaction that occurred on Saturday, April 18th. The shares were sold at an average price of $44.52, for a total transaction of $131,244.96. Following the sale, the director owned 2,964,774 shares of the company's stock, valued at approximately $131,991,738.48. The trade was a 0.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,131,856 shares of company stock valued at $50,834,773. 3.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Several hedge funds have recently bought and sold shares of SION. Russell Investments Group Ltd. bought a new stake in Sionna Therapeutics during the third quarter valued at approximately $30,000. BNP Paribas Financial Markets bought a new stake in Sionna Therapeutics during the second quarter valued at approximately $31,000. GF Fund Management CO. LTD. bought a new stake in Sionna Therapeutics during the fourth quarter valued at approximately $36,000. Balyasny Asset Management L.P. bought a new stake in Sionna Therapeutics during the fourth quarter valued at approximately $58,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Sionna Therapeutics during the fourth quarter valued at approximately $89,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.